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ABSTRACT 46 
 47 
Chromosomal region 1p22 is deleted in ≥20% of multiple myeloma (MM) patients, suggesting 48 
the presence of an unidentified tumor suppressor. Using high-resolution genomic profiling, we 49 
delimit a 58 kb minimal deleted region (MDR) on 1p22.1 encompassing two genes: ectopic 50 
viral integration site 5 (EVI5) and ribosomal protein L5 (RPL5). Low mRNA expression of 51 
EVI5 and RPL5 was associated with worse survival in diagnostic cases. Patients with 1p22 52 
deletion had lower mRNA expression of EVI5 and RPL5, however, 1p22 deletion status is a 53 
bad predictor of RPL5 expression in some cases, suggesting that other mechanisms 54 
downregulate RPL5 expression. Interestingly, RPL5 but not EVI5 mRNA levels were 55 
significantly lower in relapsed patients responding to bortezomib and; both in newly 56 
diagnosed and relapsed patients, bortezomib treatment could overcome their bad prognosis 57 
by raising their progression-free survival to equal that of patients with high RPL5 expression. 58 
In conclusion, our genetic data restrict the MDR on 1p22 to EVI5 and RPL5 and although the 59 
role of these genes in promoting MM progression remains to be determined, we identify RPL5 60 
mRNA expression as a biomarker for initial response to bortezomib in relapsed patients and 61 
subsequent survival benefit after long-term treatment in newly diagnosed and relapsed 62 
patients. 63 
64 
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INTRODUCTION 65 
 66 
Multiple myeloma (MM) accounts for up to 10% of all hematologic malignancies. Patient 67 
outcome has improved significantly in the last decade, partially due to the introduction of 68 
novel agents, such as immunomodulatory drugs (IMiDs) as well as the proteasome inhibitors 69 
(bortezomib and second generation agents carfilzomib and ixazomib). Nevertheless, not all 70 
patients respond to these new drugs, and factors determining response are still poorly 71 
understood.1,2 In the light of high costs and higher occurrence of severe side-effects such as 72 
peripheral neuropathy associated with bortezomib treatment1,3, future efforts should be 73 
directed to developing biomarkers that can identify patients that will benefit from a particular 74 
drug or drug scheme. 75 
MM, like other cancers, is caused by stepwise accumulation of genetic abnormalities. 76 
Chromosomal translocations involving the immunoglobulin heavy (IgH) locus causing 77 
overexpression of targeted oncogenes are primary events. The most prevalent of these 78 
translocations are t(11;14)(q13;q32) and t(4;14)(p16;q32), each present in 15% of cases. In 79 
the absence of IgH translocations, the disease is usually characterized by hyperdiploidy, 80 
specifically trisomy of odd chromosomes. Secondary hits then cause progression from 81 
asymptomatic monoclonal gammopathy of undetermined significance (MGUS), to smoldering 82 
myeloma, and finally to symptomatic myeloma with organ damage and bone lesions. 83 
Secondary events consist of mutations, chromosomal translocations and/or copy number 84 
changes. The mutational spectrum of MM has recently been characterized using genome 85 
wide next generation sequencing, which has revealed a heterogeneous mutational landscape 86 
with few recurrently affected genes. Only three genes have been found to be mutated in more 87 
than 10% of patients: KRAS (22% of cases), NRAS (20%) and FAM46C (12%).4-7 With regard 88 
to chromosomal abnormalities, secondary hits consist of t(8;14)(q24;q32) causing MYC 89 
activation, as well as copy number changes, with the most common ones being gains on 1q, 90 
3p, 6p, 9p, 11q, 19p, 19q and 21q along with deletions of 1p, 4q, 16q and 22q. For some of 91 
these regions, candidate oncogenes and tumor suppressors contributing to disease 92 
progression have been identified.3, 8-10 93 
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Among the deleted regions, 1p is one of the most prevalent with up to 30% of myeloma 94 
patients carrying the deletion. Four distinct minimally deleted regions (MDRs) have been 95 
identified on 1p (1p12, 1p21.3p22.1, 1p31.1 and 1p32.3), of which 1p21.3p22.1 is the most 96 
common one (15-22% of patients).11-13 This region is associated with higher incidence of 97 
t(4;14)(p16;q32) and deletion of 17p and 13q14, and is a negative prognostic factor for 98 
progression-free survival (PFS) and overall survival (OS) in newly diagnosed patients.13 Low 99 
expression of several genes on 1p22 is part of a high risk MM gene signature.14 So far, 100 
however, no tumor suppressor has been identified on this cytoband. Previously, an MDR of 101 
1p21.3p22.1 encompassing 35 genes was defined and MTF2 and TMED5 were proposed as 102 
candidate tumor suppressors in this region, as they show differential expression between 103 
deleted and non-deleted cases. However, no mutations were found in these genes, low MTF2 104 
expression does not affect PFS or OS, and the association between low TMED5 expression 105 
and shorter survival is only borderline significant.11,12 106 
To uncover potentially clinically relevant tumor suppressors on 1p22, we performed an in-107 
depth genetic analysis of 1p22 in MM. We delineate an MDR encompassing only 2 genes 108 
(EVI5 and RPL5)  and show for each of these genes that low expression is associated with 109 
lower survival in newly diagnosed but not in relapse patients. RPL5 expression is significantly 110 
lower in relapse patients with initial response to bortezomib and both newly diagnosed and 111 
relapse patients with low RPL5 expression have better PFS when bortezomib is included in 112 
their treatment scheme. We thus identify RPL5 expression levels as a novel clinical biomarker 113 
for response to bortezomib. 114 
 115 
MATERIALS AND METHODS 116 
 117 
Patient samples 118 
We studied 35 advanced diagnostic MM bone marrow samples available at UZ Leuven with at 119 
least 70% plasma cells (Supplementary Table 1). All cases were routinely characterized by 120 
FISH, as described previously.15 This study was approved by the ethical committee of the UZ 121 
Leuven. Copy number, mutation and gene expression data of the Multiple Myeloma Research 122 
Consortium (MMRC) (https://www.broadinstitute.org/mmgp/home) were also used. For 123 
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survival analyses, we analyzed data from the phase III HOVON-65/ GMMG-HD4 and APEX 124 
trials.16-18 In the phase III HOVON-65/ GMMG-HD4 trial, newly diagnosed MM patients were 125 
treated with an experimental PAD protocol (bortezomib, doxorubicin, dexamethasone with 126 
bortezomib maintenance) or a conventional VAD protocol (vincristine, doxorubicin, 127 
dexamethasone with thalidomide maintenance). In the APEX trial, bortezomib versus high-128 
dose dexamethasone monotherapy was tested in relapsed patients. All study participants 129 
provided informed consent to use their data for research purposes and all studies were 130 
conducted according to the Declaration of Helsinki. 131 
 132 
High resolution copy number arrays  133 
UZ Leuven cases were analyzed on Cytoscan HD arrays (Affymetrix). Data were processed 134 
using Chromosome Analysis Suite (ChAS) software (Affymetrix) with hg19 as reference. In 135 
order to call a deletion, we required at least 20 consecutive markers with a weighted log2 ratio 136 
of -0.15 or less. Raw data is available at NCBI as GEO accession GSE73976. 137 
 138 
Analysis of gene expression levels in patients  139 
The 245 MMRC cases with copy number and expression data available on 140 
(https://www.broadinstitute.org/mmgp/home) were analyzed. Patients with a log2 copy 141 
number ratio >-0.1 for 1p22.1 were considered non-deleted; ratios <-0.6 were considered 142 
deleted. Patients with values between -0.1 and -0.6 were excluded. 143 
 144 
Bortezomib response analysis  145 
Gene expression array data from the APEX trial were used (GSE9782). Only the bortezomib 146 
arm of the trial was used in this analysis. Patients with complete remission, partial response 147 
or minimal response were assigned to the group of responders. Patients with no change or 148 
progressive disease were considered non-responders. Probe sets with differential signal 149 
between responders and non-responders were calculated using limma (Bioconductor).19 The 150 
entire list of probe sets was ranked according to log2 fold changes and used as input for 151 
Gene Set Enrichment Analysis (GSEA) against the MSigDB C2 KEGG and C1 positional 152 
gene sets.20,21 Only GSEA results with a FDR q-value <0.2 were considered. 153 
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Survival analysis  154 
For the analysis on the phase III HOVON-65/ GMMG-HD4 trial,16 327 patients with gene 155 
expression array profiling were included (GEO ID: GSE19784)). For the APEX trial, 264 156 
patients from which gene expression array data were available were analyzed (GEO ID: 157 
GSE9782). On each of the trial datasets, Cox regression (including both arms of the trial) 158 
testing association between the indicated gene levels and survival was performed if the 159 
proportionality criterion was met (tested using covariate time analysis). Subsequently, patients 160 
were divided into groups with expression levels above the median (high expression) and 161 
below the median (low expression) or according to the specified threshold. Kaplan-Meier 162 
analysis was then performed on patients with either low or high expression to test the 163 
prognostic value of the indicated gene expression levels on survival and to test whether these 164 
patients differ in the benefit they get from each of the treatments. 165 
 166 
More details on methods are available in the supplement. 167 
 168 
RESULTS 169 
 170 
Delineation of a 58 kb MDR on 1p22.1 encompassing the EVI1 and RPL5 genes. 171 
We analyzed 35 advanced MM samples on high resolution copy number arrays 172 
(Supplementary table 1). The 1p22 cytoband, or part of it, was deleted in 15 out of 35 cases 173 
(43%), confirming the high incidence of 1p22 deletions in this disease (Figure 1A; 174 
Supplementary table 2).11-13 Loss of 1p22 was detected in cases with hyperdiploid karyotype 175 
(7/15) or IGH-mediated translocation/deletion (5/15). The most frequent aberration associated 176 
with the 1p22 loss was del(13q14/RB1) (10/15) (Supplementary table 1). For 2 cases with 177 
deletions in bone marrow at diagnosis, buccal swab DNA was available and absence of the 178 
lesion in the buccal swab was confirmed by MLPA, supporting the somatic nature of these 179 
lesions (Supplementary figure 1). 180 
To determine the MDR at 1p22, the average weighted log2 array values were calculated for 181 
each of the genes on 1p22 in our cohort (Figure 1B, Supplementary table 3), with the genes 182 
with the lowest value defining the MDR. Chromosome band 1p22.1 had lower values than 183 
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1p22.2 and 1p22.3. Of interest, patients MM05 and MM02, showed highly focal deletions of 184 
304 kb and 366 kb with an overlap of only 58 kb. The deletion in MM05 affected the 5’ parts of 185 
the EVI5 and MTF2 genes, as well as the entire RPL5 and FAM69A genes and was 186 
confirmed by FISH (Figure 1C-D). For patient MM02, it was clear that the entire GFI1 and 187 
EVI5 genes were deleted. The centromeric border in MM02 was hard to define on the array 188 
and by FISH, although it seemed within RPL5 (Figure 1C-D). To better delineate this 189 
centromeric border, the copy number status of the different exons of RPL5 was analyzed 190 
using MLPA (Figure 1E). This assay revealed that the deletion breakpoint was right within 191 
RPL5, with exons 1-4 deleted, whereas the 3’ of the gene was unaffected. We thus confirmed 192 
that RPL5 was part of the MDR. In conclusion, the MDR on 1p22.1 was restricted to a 58 kb 193 
region in our cohort, encompassing the 5’ parts of EVI5 and RPL5. EVI5 is a modulator of cell 194 
cycle progression, cytokinesis, and cellular membrane traffic. RPL5 encodes ribosomal 195 
protein L5, one of the 81 protein components of the ribosome. 196 
 197 
RPL5 and EVI5 are the genes on 1p22.1 with most predicted functionally impairing 198 
mutations 199 
We reasoned that a relevant tumor suppressor might also be targeted by mutations. 200 
Therefore, integration of the copy number data with mutation data might help in pinpointing 201 
relevant genes. Exome-wide mutation screening in large MM cohorts has been performed.4-7 202 
Whereas mutations in genes on 1p22 are rare in all of these studies, RPL5 was significantly 203 
mutated in one study with an incidence of 2/84 (2.4%).4 We analyzed the mutational load of 204 
all 1p22.1 genes in the MMRC exome data of 203 patients6 and calculated a mutation score 205 
for each gene on 1p22.1 (with a higher score referring to more mutations in a gene that are 206 
likely to impair protein function) (Figure 2A, Supplementary tables 4-5). Whereas EPHX4, a 207 
gene outside the MDR, had a high mutation score because of a relatively high number of 208 
gene size corrected mutations with low predicted functional impact, the EVI5 and RPL5 genes 209 
had the highest mutation scores (Figure 1B, Figure 2A). 210 
 211 
EVI5 and RPL5 mRNA levels are lower in 1p22.1 deleted cases 212 
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Next, we tested if deletion of 1p22 reduces RPL5 and/or EVI5 expression levels. No high 213 
quality RNA was available from our patients analyzed by copy number arrays. Therefore, we 214 
analyzed the association between gene expression and copy number status in the MMRC 215 
cohort. For both genes, expression levels were significantly lower in 1p22 deleted cases as 216 
compared to non-deleted cases (p<0.0001) (Figure 2B). However, for EVI5, there was less 217 
overlap in expression levels between 1p22 wild type and deleted cases than for RPL5, as 218 
reflected by a slightly larger fold change in expression for EVI5 than for RPL5 when 219 
comparing deleted versus non-deleted cases (0.59 versus 0.71). 220 
 221 
Low EVI5 and RPL5 expression correlates with shorter PFS and OS in newly diagnosed 222 
but not in relapse cases 223 
1p22 deletion is associated with lower PFS and OS in newly diagnosed MM.13 Since 1p22 224 
deletion status was not available for the trial data we had access to, we could not confirm this 225 
previously described correlation. We tested however if EVI5 and or RPL5 expression levels 226 
can mirror the bad prognosis of 1p22 deletion. Cox regression analysis on the data from the 227 
phase III HOVON-65/ GMMG-HD4 trial (referred to as HOVON-65 later on) on newly 228 
diagnosed cases demonstrated that lower RPL5 levels were associated with shorter PFS and 229 
OS (Table 1). In agreement with this, Kaplan-Meier analysis showed a lower median PFS and 230 
OS in patients with RPL5 expression below median (‘RPL5 low’) than in patients with RPL5 231 
expression above median (‘RPL5 high’) (Figure 3A). However, in the APEX trial on relapsed 232 
patients, no association between RPL5 levels and survival was found (Supplementary figure 233 
2; Table 1). Similarly, low EVI5 expression was associated with worse PFS and OS in the 234 
HOVON-65 but not in the APEX trial (Figure 3B and Supplementary figure 2; Table 1). 235 
Optimal cutoff for RPL5 expression in relation to survival in the HOVON-65 trial was 236 
determined at the 22.5% lowest RPL5 expressers. Using this cutoff instead of median RPL5 237 
expression gave a superior separation of patients in the HOVON-65 trial as well as in a 238 
validation cohort for which OS data were available in the R2: Genomics Analysis and 239 
Visualization Platform (Supplementary figure 3A-D). For EVI5 expression median expression 240 
was close to the best cutoff for PFS in the HOVON-65 trial while for OS, the optimal cutoff 241 
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was determined at the 31.5% lowest EVI5 expressers. Application of this cutoff in the 242 
validation cohort in R2 again confirmed the superior separation (Supplementary figure 3E-G). 243 
 244 
Bortezomib responders express lower levels of RPL5 and other ribosomal protein and 245 
translation genes 246 
Proteasome inhibitors are now included in most therapeutic schemes of MM patients. Cellular 247 
protein metabolism and homeostasis, which are probably affected by proteasome inhibitors, 248 
might also be altered by reduced expression levels of a ribosomal protein like RPL5. To 249 
investigate this potential association, data from the APEX clinical trial were analyzed. In this 250 
trial, relapse patients were treated with bortezomib or dexamethasone as single agent.17 In 251 
the bortezomib arm of the trial (n=169), RPL5 mRNA expression was significantly lower in the 252 
bortezomib responders than in non-responders (fold change responders versus non-253 
responders: 0.68, p<0.0001) (Figure 4A). When analyzing all differentially expressed genes 254 
between responders and non-responders in this trial arm, 1211 probe sets were significant 255 
(adjusted p-value < 0.2). Interestingly, the 2 probe sets that reliably detect RPL5 ranked on 256 
the 8th and 387th position when listing the genes by significance (adjusted p-values 0.014 257 
and 0.112) (Supplementary table 6). EVI5 was not present in this list of significant probe sets. 258 
The top 20 of differentially expressed probe sets seemed enriched for genes involved in 259 
translation (RPS7, RPL5, RPS21, EIF3M, RPS29 and EIF3H) (Table 2). In agreement with 260 
this and with previous results18, GSEA revealed the ribosome as top downregulated KEGG 261 
pathway in bortezomib responders versus non-responders (Figure 4B, Supplementary table 262 
7). Downregulation of the other ribosomal and translation associated genes besides RPL5 in 263 
our top 20 did not seem to be caused by 1p22 deletion associated downregulation of RPL5, 264 
because these genes did not differ in expression level between 1p22 deleted and non-deleted 265 
cases (Supplementary figure 4). However, expression of RPL5 did correlate with expression 266 
of each of these other genes (Supplementary figure 5), suggesting that other mechanisms 267 
besides 1p22 deletion are regulating expression of this entire ribosome – translation gene set 268 
in MM.  269 
Based on Cox regression analysis, only RPL5 expression was significantly associated with 270 
both PFS and OS (Supplementary figure 6A). We also ran GSEA comparing the genes 271 
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differentially expressed between bortezomib responders and non-responders versus gene 272 
sets corresponding to each chromosome cytoband. Besides 1p22, region 14q was the only 273 
other one in the list showing recurrent deletions in MM (Supplementary Table 8). On 1p22, 274 
four additional genes besides RPL5 were in the list of differentially expressed genes in 275 
bortezomib responders, but none ranked as high as RPL5 (SH3GLB1: position 841 in ranked 276 
list, LRRC8S: 157th, DR1: 342th and 643th and ZNF644: 756th) (Supplementary Table 6). 277 
These results suggest that although some other genes on 1p22 correlate with bortezomib 278 
response, expression of RPL5 is the best singular predictor. This is probably due to additional 279 
effects regulating the expression of RPL5 in MM patients, possibly regulating a set of 280 
ribosomal/translational genes as a whole. As such, in relation to bortezomib response, RPL5 281 
expression acts as a biomarker independent of 1p22 deletion. ROC analysis was performed to 282 
find an optimal cutoff to predict Bortezomib response (Supplementary figure 7). 283 
 284 
RPL5 expression levels are associated with the survival benefit of bortezomib 285 
The association between RPL5 expression levels and clinical bortezomib response raised the 286 
question whether RPL5 levels also influence the survival benefit of bortezomib treatment. To 287 
address this question, we divided the patients from the HOVON-65 trial in two groups 288 
according to RPL5 expression levels below or above median, and compared survival in the 289 
bortezomib versus non-bortezomib arm in this trial. PFS of patients with low RPL5 expression 290 
was significantly raised when they were treated on the bortezomib arm to the point that their 291 
PFS did not differ significantly anymore with PFS of RPL5 high patients (median PFS 292 
bortezomib protocol 30 months versus 19 months for non-bortezomib, p=0.03; Figure 5A, 293 
left). On the other hand PFS of RPL5 high patients was not influenced by bortezomib (median 294 
PFS 34 months versus 33 months, p=0.94; Figure 5A, right). These findings were confirmed 295 
on the PFS data from the APEX trial (Figure 5B). We performed the same analyses for EVI5, 296 
but low levels of this gene did not significantly correlate with better PFS upon bortezomib 297 
treatment (Supplementary figure 8). Cox regression analysis was also performed on the other 298 
ribosome/translation components found in the GSEA analysis. Besides low RPL5 expression, 299 
only low RPS7 expression correlated with improved PFS on bortezomib treatment in the 300 
HOVON-65 and APEX trials (Supplementary figure 6B-C). 301 
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DISCUSSION 303 
Cytoband 1p22 is deleted in ≥20% of MM patients, although no tumor suppressors have been 304 
identified. Previously, an MDR encompassing 35 genes was defined with MTF2 and TMED5 305 
proposed as candidate tumor suppressors. However, no mutations were found in these 306 
genes, low MTF2 expression does not affect survival, and the association between low 307 
TMED5 expression and shorter survival is only borderline significant.11,12 308 
We studied a cohort of 35 advanced MM patients and found that 40% of them carried a 1p22 309 
deletion with two patients having a focal deletion in the region. As such, we delineated a 58 310 
kb MDR on 1p22.1 in our cohort encompassing only two genes: EVI5 and RPL5. Interestingly, 311 
the genes in our MDR are also part of the most commonly deleted region on 1p22 in the 312 
public MMRC cohort (Supplementary figure 9). The lower resolution of the arrays used to 313 
analyze the MMRC cohort may however prohibit detection of smaller lesions affecting these 314 
genes. It is also worth noting that EVI5 and RPL5 are still part of the MRD in our cohort when 315 
removing the two cases with highly focal lesions (MM02 and MM05) from our analysis, 316 
supporting that our MRD is not purely determined by only these two cases. Although 317 
mutations in EVI5 and RPL5 are rare, they are the genes in the region with the highest 318 
frequency of mutations which are predicted to impair protein function. Additionally, as 319 
discussed below, we do find low expression of EVI5 and RPL5 to be correlated with lower 320 
PFS and OS. 321 
Data on a potential role of EVI5 in cancer are scarce and support both tumor suppression and 322 
oncogenic functions.14,22-26 Data linking RPL5 to cancer are piling up and consistently support 323 
a tumor suppressor role. First, congenital inactivating mutations and deletions in RPL5 occur 324 
in Diamond Blackfan anemia, a rare bone marrow failure syndrome with elevated cancer 325 
risks.27,28 Also, inactivating mutations in RPL5 were recently described in T-ALL and 326 
glioblastoma29,30 and RPL5 is the only gene on 1p22 that was identified as recurrently 327 
mutated in the pan-cancer project.30-32 328 
It is intriguing that RPL5 and EVI5 deletions are much more common than mutations. This 329 
may indicate that inactivation of both genes together is required to drive MM progression. On 330 
the other hand, the plot of RPL5 mRNA expression in 1p22 deleted versus non-deleted cases 331 
(Figure 2B) indicates that there are cases in which deletion status is a bad predictor of RPL5 332 
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expression level, suggesting that other mechanisms besides 1p22 deletion can downregulate 333 
RPL5 expression in MM. 334 
In the second part of this study, we looked into the clinical relevance of RPL5 and EVI5 335 
expression levels in MM. First of all, we observed a worse PFS and OS in cases with low 336 
RPL5 and EVI5 mRNA levels in the phase III HOVON-65/ GMMG-HD4 trial on newly 337 
diagnosed patients, but not in the APEX trial on relapsed patients. These data are in line with 338 
the known poor prognosis associated with 1p22 deletion at diagnosis.13 As far as we are 339 
aware, no data are available on the prognostic value of 1p22 lesions in relapse. 340 
Secondly, we found an association between low RPL5 mRNA levels and initial response to 341 
bortezomib in relapse patients. Due to the lack of copy number data of the patients in the 342 
HOVON-65 and APEX trials, we could not test association between 1p22 deletion and 343 
bortezomib response. Our GSEA analysis for chromosomal regions enriched in the signature 344 
of responders did identify cytoband 1p22, but this enrichment was not as convincing as the 345 
enrichment we saw for downregulation of ribosome components. These results again indicate 346 
that the expression of ribosomal proteins is downregulated by additional mechanisms other 347 
than 1p22 deletion, which may make expression levels of ribosomal proteins and RPL5 in 348 
particular, more reliable to stratify patients for bortezomib response than 1p22 deletion. 349 
Although RPL5 expression may be useful to predict response to bortezomib in relapse 350 
patients, validation in an independent dataset is required. In addition, in the relapse patients 351 
tested, RPL5 levels were not perfectly associated with response, suggesting that adding as 352 
yet unknown markers may achieve this. 353 
Thirdly, survival analysis showed that in addition to initial response, low RPL5 expression is 354 
also correlated with significantly longer PFS for patients treated with bortezomib both upon 355 
diagnosis and after relapse. Unfortunately, we were unable to analyze OS data because of 356 
cross-over of patients with progressive disease to an alternative treatment in both trials.16 357 
Although the introduction of bortezomib has greatly improved prognosis of MM, it has been 358 
shown before that outcomes vary significantly among patient groups.8, 33 Therefore, Terragna 359 
et al. recently aimed to molecularly characterize complete response (CR) to bortezomib in 360 
diagnostic MM. In line with our results, they found loss of a region on 1p22 to be the CNV 361 
most significantly associated with CR after bortezomib treatment.34 Interestingly, the 660 kb 362 
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region identified by them includes EVI5 but not RPL5. However, the size of RPL5 and the 363 
resolution of their copy number arrays may prevent proper delineation of the boundary of the 364 
deleted area, as we also needed to perform MLPA and FISH to confirm that RPL5 was 365 
included in one of our focal deletions. Additionally, they list another overlapping region on 366 
1p22 as significantly associated with CR that does include RPL5. Terragna and colleagues 367 
did not find RPL5 to be significantly downregulated on mRNA level in CR cases. We suspect 368 
however that this could be because of the limited number of patients they analyzed. We also 369 
only see a slight reduction in the MMRC cohort which might escape statistical cutoff in smaller 370 
cohorts. 371 
Previously, mutations in NRAS have been associated with lower response rates to single-372 
agent bortezomib treatment35 while high tight junction protein 1 (TJP1) mRNA expression has 373 
been linked to a greater likelihood of responding to bortezomib.36,37 Indeed, both NRAS and 374 
TJP1 are ranked highly in our list of genes differentially expressed between responders and 375 
non-responders (Supplementary table 6). Additionally, proteomics profiling on diagnostic MM 376 
patient cells revealed that responders of bortezomib based protocols are characterized by 377 
altered expression of EIF2 signaling and by extension in refractory patients by altered 378 
expression of a subset of ribosomal proteins.38 379 
In conclusion, our genetic analyses narrow down the MDR on 1p22 to two genes: EVI5 and 380 
RPL5, although the exact role of these genes in promoting MM progression remains to be 381 
determined. Survival analysis shows EVI5 and RPL5 expression are associated with worse 382 
survival in newly diagnosed patients. In addition, low RPL5 expression levels are linked to 383 
initial bortezomib response in relapse patients and to survival benefit on bortezomib treatment 384 
for both diagnostic and relapse patients, leading to a complete recovery of the bad prognosis 385 
of low RPL5 levels. We thus identify RPL5 mRNA expression as a novel biomarker correlating 386 
with benefit from bortezomib treatment. 387 
  388 
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FIGURE LEGENDS 522 
 523 
Figure 1. Genetic analysis of chromosomal region 1p22 reveals RPL5 and EVI5 as 524 
candidate tumor suppressors  525 
(A) Ideogram of chromosome 1 with indication of the size of the 1p22 deletions detected in 526 
this study. (B) Average weighted log2 array ratio of 1p22 genes. Each dot in the graph 527 
represents a gene on 1p22, and genes are represented from telomeric (left, 85 Mbp) to 528 
centromeric (right, 95 Mbp). The region that shows the lowest average weighted log2 array 529 
ratio defining the MDR in our cohort is indicated in red and gene names are shown. (C) Focal 530 
1p22.1 deletions in cases MM05 and MM02. Deleted areas are indicated by the grey shaded 531 
areas, the dark grey shaded area shows the overlapping deleted region (MDR). (D) FISH with 532 
probes RP11-1E09 and RP11-456E23 on bone marrow of patients MM05 and MM02. 533 
Schematic representation of the genomic region targeted by the FISH probes is shown in 534 
panel C. Note loss of one RP11-1E09 (green) signal in MM02 and loss of one RP11-456E23 535 
(green) signal in MM05. The latter case displayed both RP11-1E09 (red) signals, because the 536 
BAC covers a larger region than the deleted sequences in MM05. (E) MLPA assay confirming 537 
deletion of exon 1-4 of the RPL5 gene in case MM02. The assay measures copy number of 538 
exons of several ribosomal protein genes. Peaks representing signals that correspond to 539 
exons of RPL5 are indicated, with deleted exons in red and non-deleted exons in black.  540 
 541 
Figure 2. EVI5 and RPL5 show the highest incidence of mutations predicted to impair 542 
protein function and their expression levels correlate with 1p22 deletion status 543 
(A) Mutation score for all 1p22.1 genes. Mutation score per gene was calculated by taking the 544 
mutation count for each gene and by correcting this value for gene length and predicted 545 
functional impact of the mutations. The MDR identified in Figure 1B is again indicated in red. 546 
(B) Gene expression plots of EVI5 (probe set 209717_s_at) and RPL5 (200937_s_at) in 1p22 547 
wt versus deleted cases. The red horizontal lines indicate the average value in the group and 548 
the standard deviations. p-values were calculated using a 2-tailed Mann-Whitney test. The 549 
fold change below the plot indicates the fold downregulation in 1p22 deleted cases.  550 
 551 
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Figure 3. Low EVI5 and RPL5 expression correlates with shorter PFS and OS in newly 552 
diagnosed but not in relapse patients 553 
(A) Kaplan-Meier curves comparing PFS (left) and OS (right) of RPL5 low and high 554 
expressing cases in the phase III HOVON-65/ GMMG-HD4 trial. (B) PFS and OS of EVI5 low 555 
and high expressing cases in the phase III HOVON-65/ GMMG-HD4 trial. ‘Low’ and ‘high’ are 556 
defined here as expression below and above median. p-values were calculated with Log-rank 557 
tests. 558 
 559 
Figure 4. Reduced expression of RPL5 and other ribosomal proteins correlates with 560 
response to bortezomib 561 
(A) Gene expression plots of RPL5 (probe set 200937_s_at) in bortezomib responders and 562 
non-responders in the APEX trial. The red horizontal lines indicate the average value in the 563 
group and the standard deviations. P-values were calculated using a 2-tailed Mann-Whitney 564 
test. The fold change indicates the fold downregulation in responders. (B) GSEA plot 565 
supporting downregulation of the genes in KEGG pathway ‘ribosome’ in bortezomib 566 
responders. 567 
 568 
Figure 5. RPL5 expression levels are associated with the benefit of bortezomib on PFS  569 
(A) Kaplan-Meier curves comparing PFS of RPL5 low (left) and high (right) expressing 570 
patients for bortezomib versus non-bortezomib arms in the HOVON-65/ GMMG-HD4 trial. (C) 571 
Kaplan-Meier curves comparing PFS of RPL5 low (left) and high (right) expressing patients 572 
for bortezomib versus dexamethasone arms in the APEX trial. Low and high expression are 573 
defined here as below and above median. All p-values were calculated with Log-rank tests. 574 
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Table 1. Cox regression values
Cox regression analysis of OS and PFS (Figure 3)
Exp (B) 95% CI p HR 95% CI p
HOVON-65/GMMG-HD4
RPL5 0.81 0.70-0.93 0.003 0.78 0.65-0.93 0.006
EVI5 0.89 0.79-1.01 0.072 0.78 0.65-0.93 0.006
APEX
RPL5 1 0.85-1.14 0.848 1.03 0.89-1.21 0.677
EVI5 0.98 0.85-1.12 0.731 0.89 0.76-1.04 0.149
Cox regression analysis on PFS  in RPL5  low versus high expressing cases 
for bortezomib versus control treatment (Figure 5)
Exp (B) 95% CI p
HOVON-65/GMMG-HD4
RPL5 low: Bz vs. CTRL 0.67 0.47-0.96 0.03
RPL5 high: Bz vs. CTRL 0.99 0.69-1.41 0.9
APEX
RPL5 low: Bz vs. CTRL 0.57 0.37-0.89 0.01
RPL5 high: Bz vs. CTRL 0.95 0.59-1.51 0.8
PFS
PFS OS
Table 2. Top 20 of probe sets with differential signal in bortezomib responders versus non-responders in the APEX trial
Probe Gene log2FC P adj.
210532_s_at C14orf2 -0.408 0.002
225335_at ZNF496 -0.540 0.002
217988_at CCNB1IP1 -0.590 0.002
229586_at CHD9 0.424 0.008
224985_at NRAS -0.470 0.008
224616_at DYNC1LI2 0.459 0.014
213941_x_at RPS7 -0.340 0.014
200937_s_at RPL5 ; SNORD21 -0.553 0.014
206790_s_at NDUFB1 -0.388 0.019
200834_s_at RPS21 -0.431 0.019
202232_s_at EIF3M -0.521 0.019
224841_x_at GAS5 ; SNORD44 ; SNORD47 ; SNORD74 ; SNORD76 ; SNORD77 ; SNORD79 ; SNORD80 ; SNORD81 -0.854 0.019
224741_x_at GAS5 ; SNORD44 ; SNORD47 ; SNORD74 ; SNORD76 ; SNORD77 ; SNORD79 ; SNORD80 ; SNORD81 -0.879 0.019
221180_at MAP3K19 0.580 0.019
208752_x_at NAP1L1 -0.406 0.019
213846_at COX7C -0.394 0.019
238025_at MLKL 0.607 0.019
200921_s_at BTG1 -0.666 0.019
201094_at RPS29 -0.419 0.019
201592_at EIF3H -0.383 0.020
